Ablative Radiotherapy for Metastatic Cancer

Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry

Recruiting Observational Study
Oligometastasis Metastatic Cancer
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
300 (estimated)
Sponsor
Duke University · Other
Who this trial is looking for

This trial is looking for adults who have been diagnosed with metastatic cancer and are receiving or will receive ablative radiotherapy. Participants will be monitored for any side effects from the treatment.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am at least 18 years old.
  • I have evidence of metastatic disease.
  • I plan to receive or am currently receiving ablative radiotherapy.
  • I have signed the study-specific informed consent.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years of age * Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment * Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablat…
Contacts

Clinical Trials Office

(919) 668 3726

RadOnc-Clinical_Trials@dm.duke.edu

CONTACT